Clinical Trial Update: A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab in combination with Nb-paclitaxel for advanced or metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Nb-paclitaxel (Nb-paclitaxel)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN